From Alphastreet - Earnings Decoded. Market Intelligence Delivered · AlphaStreet Newsdesk · · 1m
Elevance Health Q3 2026 Earnings Beat
Elevance Health tops Q3 2026 earnings estimates with $6.99 EPS, raising full-year baseline to $26.75.
In brief
Elevance Health tops Q3 2026 earnings estimates with $6.99 EPS, raising full-year baseline to $26.75. Elevance Health reported Q3 2026 adjusted EPS of $6.99, beating estimates by 47.8% and raising full-year earnings baseline to $26.75. Originally reported by Alphastreet - Earnings Decoded. Market Intelligence…
Q3 2026 Earnings Beat
Elevance Health delivered adjusted EPS of $6.99 against a consensus estimate of $4.73.
EPS Growth and Margin Expansion
The company reported 16% year-over-year EPS growth to $6.99 with 2.7% net margin.
Revenue Stagnation
Q3 revenue increased 0.7% to $50.44 billion from $50.71 billion in Q3 2025.
Segment Performance
Health Benefits generated $43.36 billion with 2.6% growth, CarelonRx $11.60 billion with 5.5% growth.
Management Guidance
Management raised full-year earnings baseline by $0.75 to at least $26.75 and projects 12% eps growth in 2027.
“our earnings baseline increases by $0.75 to at least $26.75, reflecting third quarter operating outperformance and an improved full-year outlook for individual ACA”
Market Reaction
Stock rose 2.3% to $440.18 despite the earnings beat.
What to Watch
Q4 results will test if raised baseline is conservative and membership trends impact revenue growth.
The takeaway
Elevance Health reported Q3 2026 adjusted EPS of $6.99, beating estimates by 47.8% and raising full-year earnings baseline to $26.75.
